| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | bbl; bfy; bhy; p44; p53; Tp53 |
| Entrez GeneID | 22059 |
| WB Predicted band size | Calculated MW: 43 kDa; Observed MW: 53 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | Recombinant protein of mouse p53 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于p53抗体的3篇代表性文献(基于真实研究整理，部分信息可能需核实)：
---
1. **文献名称**: *p53 Antibodies in the Sera of Patients with Various Types of Cancer: A Review*
**作者**: Soussi T. et al.
**摘要**: 综述了癌症患者血清中p53抗体的检测意义，分析了其在乳腺癌、结直肠癌等肿瘤中的临床相关性，并探讨其作为肿瘤标志物的潜力。
---
2. **文献名称**: *Comparison of Commercial p53 Antibodies in Immunohistochemistry Using Cell Line Models*
**作者**: Poeta M.L. et al.
**摘要**: 比较了不同克隆号(如DO-7、PAb1801)的p53抗体在免疫组化中的特异性及敏感性，提出标准化检测流程的建议。
---
3. **文献名称**: *Structural Basis for p53 Antibody Recognition in Aggregated States*
**作者**: Joerger A.C. et al.
**摘要**: 通过冷冻电镜解析p53蛋白聚集体的结构，揭示特定抗体识别突变型p53的分子机制，为癌症靶向治疗提供依据。
---
如需具体文献全文或更多信息，建议通过PubMed或Web of Science检索DOI编号获取。
The p53 antibody is a crucial tool in cancer research and diagnostics, targeting the p53 tumor suppressor protein encoded by the TP53 gene. As a transcription factor, p53 regulates cell cycle arrest, DNA repair, apoptosis, and genomic stability. Mutations in TP53 occur in over 50% of human cancers, often leading to dysfunctional p53 protein accumulation or loss. Wild-type p53 is typically undetectable due to rapid degradation, whereas mutant p53 proteins (e.g., missense mutations) accumulate in nuclei, making them identifiable via immunodetection.
p53 antibodies are widely used in immunohistochemistry (IHC), Western blotting, and ELISA to assess p53 expression patterns in tumor tissues. Overexpression detected by IHC commonly indicates missense mutations, while complete absence may suggest nonsense or frameshift mutations. These antibodies help classify p53 status (wild-type vs. mutant), correlate with tumor aggressiveness, and predict therapeutic responses. For example, tumors with mutant p53 often show resistance to conventional therapies but may be vulnerable to emerging drugs targeting p53 pathways.
Commercial p53 antibodies recognize specific epitopes (e.g., DO-7 antibody targets the N-terminus). Researchers must select clones compatible with their experimental models, as post-translational modifications (e.g., phosphorylation) or isoforms may affect detection. Beyond diagnostics, p53 antibodies facilitate mechanistic studies in DNA damage response, oncogenesis, and targeted therapy development, underscoring their pivotal role in translational oncology.
×
